We have been progressing with the development of our new OP-724 (PRI-724) product for the treatment of liver cirrhosis caused by HCV.

In recent years, the advancement of antiviral agents against hepatitis C virus (HCV) has enabled the elimination of HCV infections, but there have been no effective treatment options for decompensated cirrhosis, which is severe cirrhosis.

OP-724 has demonstrated some efficacy as a compound having the ability to improve liver fibrosis, which is a problem in liver cirrhosis. We are working diligently on the development of this compound in the aim of being able to provide this treatment option for liver cirrhosis patients.